alzheimers

More harm than good???

• Donepezil has not been demonstrated to improve outcomes of importance to patients and caregivers (e.g. institutionalization or disability). Rivastigmine and galantamine have not been studied for these outcomes.
• AChE-I cause gastrointestinal, muscular, and other adverse effects and likely increase serious adverse events.
• There is no evidence that stopping AChE-I treatment is harmful.
• In advanced AD, memantine has not been demonstrated to improve outcomes of importance to patients and caregivers.